Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Ruxolitinib

Brand: Jakavi®
NICE TA: 386
Indication: Treating disease-related splenomegaly or symptoms in adults with myelofibrosis (NICE TA386)
Disease category: Malignant disease and immunosuppression
Commissioning responsibility: NHS England
PbR excluded: Yes

Background

April 2016 — entry updated following NICE TA386 replacing NICE TA289.

Ruxolitinib is recommended as an option for treating disease-related splenomegaly or symptoms in adults with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only:
- in people with intermediate‑2 or high-risk disease, and
- if the company provides ruxolitinib with the discount agreed in the patient access scheme

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red